65 citations
,
June 2020 in “Stem Cell Research & Therapy” Certain immune system proteins are important for skin healing but can cause problems if there are too many of them.
April 2024 in “Journal of cancer research and clinical oncology” Tissue-derived extracellular vesicles are crucial for cancer diagnosis, prognosis, and treatment.
December 2022 in “Sudan Journal of Medical Sciences” Vaccination is the most effective way to reduce COVID-19 transmission.
170 citations
,
September 2019 in “Evidence-based Complementary and Alternative Medicine” Some medicinal plants can help heal wounds and may lead to new treatments.
316 citations
,
June 2017 in “Stem Cell Research & Therapy” Fat tissue-derived cells show promise for repairing body tissues, but more research and regulation are needed for safe use.
51 citations
,
June 2016 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.
50 citations
,
March 2021 in “Journal of investigational allergology & clinical immunology” Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.
34 citations
,
September 2020 in “BMC Endocrine Disorders” Existing drug dexamethasone may lower death risk in severe COVID-19 cases; more research needed for other drugs.
22 citations
,
April 1998 in “Dermatologic Clinics” Interferons are effective for some skin conditions and cancers, but can have side effects and need more research for optimal use.
9 citations
,
February 2022 in “Nature communications” Rare changes in the KRT82 gene are linked to a higher risk of Alopecia Areata.
6 citations
,
March 2021 in “Cytotechnology” Mesenchymal stem cells show promise in treating COVID-19 by reducing inflammation and aiding recovery, but more research is needed.
2 citations
,
November 2025 in “Frontiers in Immunology” Females are more affected by immune-related skin diseases, needing targeted health interventions.
1 citations
,
January 2026 in “Dermatology Reports” Tildrakizumab may cause alopecia areata, but stopping it and using corticosteroids can regrow hair.
14 citations
,
September 2018 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” A boy's growth and immune problems were caused by a new mutation in the STAT5B gene.
2 citations
,
September 2024 in “Expert Opinion on Drug Metabolism & Toxicology” Ritlecitinib is an effective new treatment for Alopecia Areata.
February 2026 in “Figshare” A new hydrogel treatment reduces inflammation and promotes hair growth in alopecia areata.
February 2026 in “Figshare” A new hydrogel treatment reduces inflammation and promotes hair growth in alopecia areata.
July 2024 in “Journal of Investigative Dermatology” Brepocitinib improves cicatricial alopecia and reduces key immune markers.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” OR-101 shows promise for treating alopecia areata by improving hair growth.
January 2025 in “Skin Health and Disease” Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
1 citations
,
October 2025 in “Journal of Allergy and Clinical Immunology” A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Quercetin and kaempferol may be effective and safe natural treatments for hair loss.
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Quercetin and kaempferol may be effective and safe natural treatments for hair loss.
5 citations
,
March 2023 in “International Journal of Trichology” Alopecia areata patients may have higher cardiovascular risk factors, so screening for metabolic syndrome components is suggested.
January 2026 in “Cytokine” Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
March 2025 in “Clinical Cosmetic and Investigational Dermatology” The Tru9I variant in the VDR gene may influence alopecia areata risk and vitamin D levels.
July 2024 in “Journal of Investigative Dermatology” OR101 may effectively treat atopic dermatitis and similar skin conditions.
16 citations
,
December 2015 in “Journal of Investigative Dermatology” Alopecia areata involves persistent gene abnormalities and immune activity, even in regrown hair, suggesting a risk of relapse.
Baricitinib showed mixed results in treating alopecia areata in children, with some improvement but also side effects.